Datasheet

BCL6 Antibody
CATALOG NUMBER: 6985

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:BCL6 antibody can be used for detection of BCL6 by Western blot at 1 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1462 - Rat Lung Tissue Lysate
PREDICTED MOLECULAR WEIGHT:78 kDa
SPECIFICITY:Three alternatively spliced transcript variants have been observed
IMMUNOGEN:BCL6 antibody was raised against an 18 amino acid synthetic peptide near the center of human BCL6.

The immunogen is located within amino acids 370 - 420 of BCL6.
HOST SPECIES:Rabbit

Properties

PURIFICATION:BCL6 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:BCL6 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:BCL6 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:BCL6 Antibody: BCL5, LAZ3, BCL6A, ZNF51, ZBTB27, BCL5, B-cell lymphoma 6 protein, B-cell lymphoma 5 protein, BCL-6
ACCESSION NO.:NP_001124317
PROTEIN GI NO.:195927002
OFFICIAL SYMBOL:BCL6
GENE ID:604

Background

BACKGROUND:BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML).
REFERENCES: 1) Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 1995; 14:6209-17.
2) Dent AL, Shaffer AL, Yu X, et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science1997; 276:589-92.
3) Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 1997; 16:161-70.
4) Hurtz C, Hatzi K, Cerchietti L, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 2011; 208:2163-74.

For Research Use Only